GlassScriptPhysician profile
Staci M Kallish
NPI 1811152796
$189,241.52
in general payments reported to CMS, 2019-2025
6 companies · $60K in 2025
The $60K reported for 2025 was more than what 95% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,115 · 2020: $6,015 · 2021: $5,992 · 2022: $15K · 2023: $40K · 2024: $56K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $113K · Travel and Lodging: $28K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,442 · Honoraria: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $113,004.00 |
| Travel and Lodging | $28,228.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,784.00 |
| Food and Beverage | $2,442.23 |
| Honoraria | $1,560.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amicus Therapeutics, INC. | $118,050.37 | 2019-2025 | Galafold, Pombiliti, Opfolda |
| Genzyme Corporation | $62,984.74 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $6,604.17 | 2022-2024 | |
| Intrabio INC | $1,560.00 | 2025 | Aqneursa |
| Sanofi-Aventis U.S. LLC | $42.24 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Staci Kallish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.